Online citations, reference lists, and bibliographies.
← Back to Search

Treatment Of Psychosis And Dementia In Parkinson’s Disease

J. Goldman, Samantha K Holden
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Opinion statementParkinson’s disease (PD) has been increasingly recognized as having a multitude of nonmotor symptoms including psychosis, cognitive impairment and dementia, mood disturbances, fatigue, apathy, and sleep disorders. Psychosis and dementia, in particular, greatly affect quality of life for both patients and caregivers and are associated with poor outcomes. Safe and effective treatment options for psychosis and dementia in PD are much needed. Antipsychotics with dopamine-blocking properties can worsen parkinsonian motor features and have been associated with increased morbidity and mortality in elderly, dementia patients. For treating PD psychosis, a first step would be eliminating confounding variables, such as delirium, infections, or toxic-metabolic imbalances, followed by simplifying parkinsonian medications as tolerated. If additional treatment is warranted after such interventions, clozapine or quetiapine can be implemented at the low dose levels typically needed by PD patients. Although quetiapine is easy-to-use in clinical settings, does not require blood count monitoring like clozapine, and is anecdotally beneficial, it remains “investigational” in evidence-based medicine reviews. Though not currently available, the novel 5-HT2a inverse agonist, pimavanserin has shown promise in the treatment of PD psychosis. Current treatments for PD dementia are mostly derived from those utilized in Alzheimer’s disease, focusing mainly on cholinesterase inhibitors and memantine, a NMDA receptor antagonist. Rivastigmine, the only Food and Drug Administration approved medication for PD dementia, is a reasonable first choice. Other cholinesterase inhibitors and memantine have not yet achieved recommendation status in evidence-based medicine reviews but are well tolerated in studies of PD dementia patients. At present, there are no approved treatments for mild cognitive impairment in PD, but rasagiline, a selective MAO-B inhibitor, and atomoxetine, a serotonin norepinephrine reuptake inhibitor, have been recently studied. Nonpharmacological interventions, including cognitive therapy, physical activity, music and art therapy, and noninvasive brain stimulation techniques, may be promising options for PD cognitive impairment but await rigorous study.
This paper references
10.1176/AJP.135.6.669
Levodopa-induced psychosis: a kindling phenomenon.
C. Moskovitz (1978)
10.1212/WNL.43.5.986
The locus ceruleus and dementia in Parkinson's disease
R. Zweig (1993)
10.1212/WNL.43.11.2227
Risk factors for nursing home placement in advanced Parkinson's disease
C. Götz (1993)
10.1212/WNL.45.4.669
Mortality and hallucinations in nursing home patients with advanced Parkinson's disease
C. Götz (1995)
10.1001/ARCHNEUR.1996.00550120077019
Visual hallucinations associated with Parkinson disease.
J. Sanchez-Ramos (1996)
10.1212/WNL.50.3_SUPPL_3.S1
An algorithm (decision tree) for the management of Parkinson's disease
C. W. Olanow (1998)
10.1097/00008483-200005000-00012
Therapeutic value of exercise training in Parkinson's disease.
I. Reuter (1999)
Ther - apeutic value of exercise training in Parkinson ' s disease
I Reuter (1999)
10.1212/WNL.55.6.789
Olanzapine and clozapine
C. Götz (2000)
10.1111/j.1532-5415.2000.tb06891.x
Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study
D. Aarsland (2000)
10.1093/BRAIN/123.4.733
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.
G. Fénelon (2000)
10.1002/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q
Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial
S. Factor (2001)
10.1212/WNL.56.SUPPL_5.S1
An algorithm (decision tree) for the management of Parkinson’s disease (2001):
C. W. Olanow (2001)
10.1002/mds.1204
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial
P. J. Reading (2001)
10.1007/s100720200084
Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease
L. Morgante (2002)
10.1212/WNL.58.1.156
An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines
S. Frucht (2002)
10.1136/jnnp.72.6.708
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
D. Aarsland (2002)
10.1097/00002826-200203000-00009
Successful Use of Donepezil for the Treatment of Psychotic Symptoms in Patients With Parkinson's Disease
Joseph A. Bergman (2002)
10.1016/S0006-3223(02)01392-6
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease
A. Breier (2002)
10.1007/s100720200022
Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
G. Fabbrini (2002)
10.1002/mds.10217
Olanzapine treatment for dopaminergic‐induced hallucinations
W. Ondo (2002)
10.1185/030079902125000813
Rivastigmine for the Treatment of Dementia and Visual Hallucinations Associated with Parkinson's Disease: A Case Series
R. Bullock (2002)
Olanzapine treatment for dopaminergicinduced hallucinations
WG Ondo (2002)
10.1001/ARCHNEUR.60.3.387
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.
D. Aarsland (2003)
10.1002/14651858.CD003672
Cholinesterase inhibitors for dementia with Lewy bodies.
R. Wild (2003)
10.1177/0891988703256054
The Beneficial Effect of Donepezil on Visual Hallucinations in Three Patients with Parkinson's Disease
A. Kurita (2003)
10.1016/S0035-3787(04)70942-X
[Hallucinations and dementia. Prevalence, clinical presentation and pathophysiology].
G. Fénelon (2004)
10.1016/J.ARCHGER.2004.04.049
Cognitive rehabilitation in Parkinson's disease.
E. Sinforiani (2004)
10.1002/GPS.993
Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
I. Leroi (2004)
10.1056/NEJMOA041470
Rivastigmine for dementia associated with Parkinson's disease.
M. Emre (2004)
10.1097/00002826-200401000-00003
Aripiprazole for Drug-Induced Psychosis in Parkinson Disease: Preliminary Experience
H. Fernandez (2004)
10.1007/s00441-004-0956-9
Stages in the development of Parkinson’s disease-related pathology
H. Braak (2004)
Prevalence, clinical presentation and pathophysiology
G Fenelon (2004)
Mahieux F [ Hallucinations and dementia . Prevalence , clinical presentation and pathophysiology ]
G Fenelon (2004)
Randomized placebocontrolled trial of donepezil in cognitive impairment in Parkinson’s disease
I Leroi (2004)
10.1212/01.wnl.0000187889.17253.b1
Diagnosis and management of dementia with Lewy bodies
I. McKeith (2005)
10.1136/jnnp.2004.050682
Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study
B. Ravina (2005)
10.4088/JCP.V66N0514
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias.
D. Aarsland (2005)
10.1097/01.wnf.0000172498.24770.54
Efficacy and Safety of Donepezil in the Treatment of Executive Dysfunction in Parkinson Disease: A Pilot Study
G. Linazasoro (2005)
10.1002/mds.20474
Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease
W. Ondo (2005)
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology
IG McKeith (2005)
10.1016/j.jns.2006.05.028
Training of executive functions in Parkinson's disease
G. Sammer (2006)
10.1016/j.jns.2006.05.062
Effects of transcranial direct current stimulation on working memory in patients with Parkinson's disease
P. Boggio (2006)
10.1007/BF03074779
Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson
J. Rovers (2006)
10.1038/sj.mp.4001763
Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine
E T Tzavara (2006)
10.1002/mds.21077
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease
D. Burn (2006)
10.1002/mds.21091
Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
J. Friedman (2006)
10.1212/01.wnl.0000215428.46057.3d
Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
J. Miyasaki (2006)
10.1002/mds.20965
Neuropsychological deficits in Parkinson's disease patients with visual hallucinations
B. Ramírez-Ruíz (2006)
10.1097/01.WNF.0000236769.31279.19
Rater-blinded, Prospective Comparison: Quetiapine Versus Clozapine for Parkinson's Disease Psychosis
D. Merims (2006)
Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease
Rovers Jm (2006)
[Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease].
J. Rovers (2006)
10.1212/01.WNL.0000215428.46057.3D
Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
D. Aarsland (2007)
10.1159/000101512
Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 24-Week Open-Label Study
K. Edwards (2007)
10.1212/01.wnl.0000256715.13907.d3
DLB and PDD boundary issues
C. Lippa (2007)
10.1002/mds.21844
Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
B. Dubois (2007)
10.1002/mds.21382
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
B. Ravina (2007)
10.1002/mds.21116
Effect of quetiapine in psychotic Parkinson's disease patients: A double‐blind labeled study of 3 months' duration
J. Rabey (2007)
10.1002/mds.21507
Clinical diagnostic criteria for dementia associated with Parkinson's disease
M. Emre (2007)
10.1212/01.wnl.0000252956.34585.a6
Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
D. Aarsland (2007)
10.1002/mds.21864
A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia
J. Pagonabarraga (2008)
10.1002/mds.21922
The effectiveness of exercise interventions for people with Parkinson's disease: A systematic review and meta‐analysis
Victoria A. Goodwin (2008)
10.1002/mds.21956
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
M. Hely (2008)
10.1002/mds.22246
Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia
J. Kulisevsky (2008)
10.1136/jnnp.2008.144048
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease
J. Grace (2008)
10.1136/jnnp.2007.116202
Executive functions are impaired in patients with Parkinson’s disease with visual hallucinations
J. Barnes (2008)
10.1007/s11055-008-9077-3
Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)
I. Litvinenko (2008)
10.1007/s00401-008-0344-8
The progression of pathology in longitudinally followed patients with Parkinson’s disease
G. Halliday (2008)
10.1002/mds.22495
Randomized controlled trial of memantine in dementia associated with Parkinson's disease
I. Leroi (2009)
10.1016/S1474-4422(09)70146-2
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
D. Aarsland (2009)
10.1038/nrneurol.2009.62
Hallucinations in Parkinson disease
N. Diederich (2009)
10.2147/NDT.S5335
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
P. Shotbolt (2009)
10.1007/s00702-009-0259-0
Effect of high frequency repetitive transcranial magnetic stimulation on reaction time, clinical features and cognitive functions in patients with Parkinson’s disease
S. Sedlackova (2009)
10.3109/00207450903222758
QUETIAPINE IMPROVES VISUAL HALLUCINATIONS IN PARKINSON DISEASE BUT NOT THROUGH NORMALIZATION OF SLEEP ARCHITECTURE: RESULTS FROM A DOUBLE-BLIND CLINICAL-POLYSOMNOGRAPHY STUDY
H. Fernandez (2009)
10.1212/01.wnl.0000338632.00552.cb
Cognitive impairment in incident, untreated Parkinson disease
D. Aarsland (2009)
10.1016/j.bandc.2008.09.008
Benefits of physical exercise on executive functions in older people with Parkinson’s disease
Kátia Tanaka (2009)
10.1002/mds.22643
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease
P. Barone (2009)
10.1002/mds.22307
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study
L. Marsh (2009)
Cognitive impairment in incident , untreated Parkinson disease : the Norwegian ParkWest study
D Aarsland (2009)
10.1002/mds.23411
Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease
G. Llebaria (2010)
10.1002/mds.22646
Four novel mutations in the GCH1 gene of Chinese patients with dopa‐responsive dystonia
L. Cao (2010)
10.1007/s00702-010-0578-1
Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer’s disease: a proof of concept study
Jonathan Bentwich (2010)
10.1016/S1474-4422(10)70194-0
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
M. Emre (2010)
10.1002/mds.23083
Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations
P. Huot (2010)
10.1002/mds.22839
The changing face of Parkinson's disease‐associated psychosis: A cross‐sectional study based on the new NINDS‐NIMH criteria
G. Fénelon (2010)
10.1159/000322198
Rationale for Combined Exercise and Cognition-Focused Interventions to Improve Functional Independence in People with Dementia
J. Thom (2010)
10.1212/WNL.0b013e3181f39d0e
Mild cognitive impairment in Parkinson disease
D. Aarsland (2010)
10.1159/000316119
Nonpharmacological Therapies in Alzheimer’s Disease: A Systematic Review of Efficacy
J. Olazarán (2010)
10.1016/j.jns.2009.08.014
Epidemiology of psychosis in Parkinson's disease
G. Fénelon (2010)
10.1212/WNL.0b013e3181ebdd79
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
D. Weintraub (2010)
Mild cognitive impairment in Parkinson disease : a multicenter pooled analysis
D Weintraub (2010)
A multicenter, placebo controlled, double blind trial to examine the safety and efficacy of pimavanserin in the treatment of psychosis in Parkinson’s disease
JH Friedman (2010)
10.3389/fneur.2011.00082
Cognitive Rehabilitation in Parkinson’s Disease: Evidence from Neuroimaging
C. Nombela (2011)
10.1002/mds.23884
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
K. Seppi (2011)
10.1001/archneurol.2011.139
Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis.
D. Weintraub (2011)
10.1002/mds.23688
Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease
Anna Prats París (2011)
10.1002/mds.23175
Neuropsychiatric symptoms in Parkinson's disease
J. Friedman (2011)
10.1111/j.1600-0404.2010.01338.x
Exercise and Parkinson’s: benefits for cognition and quality of life
K. E. Cruise (2011)
10.4061/2011/675630
New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges
J. Goldman (2011)
10.1002/mds.23738
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study
H. Hanagasi (2011)
10.1123/JAPA.19.2.87
Changes in executive function after acute bouts of passive cycling in Parkinson's disease.
A. Ridgel (2011)
10.1002/mds.23835
Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years
C. Goetz (2011)
10.1177/0891988711402350
Feasibility and Acceptance of a Nonpharmacological Cognitive Remediation Intervention for Patients With Parkinson Disease
J. Mohlman (2011)
10.1002/mds.23823
MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
I. Litvan (2011)
10.1002/mds.23664
Parkinson's disease: The quintessential neuropsychiatric disorder
D. Weintraub (2011)
10.1155/2012/687909
Effect of Transcranial Brain Stimulation for the Treatment of Alzheimer Disease: A Review
R. Nardone (2012)
10.1016/j.brainres.2012.02.073
Efficacy of tailored computer-based neurorehabilitation for improvement of movement initiation in Parkinson's disease
E. Disbrow (2012)
10.1002/mds.25098
Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
B. Dubois (2012)
10.1002/mds.24893
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
I. Litvan (2012)
10.1002/14651858.CD006504.pub2
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
M. Rolinski (2012)
10.1155/2012/512892
Cognitive Rehabilitation for Executive Dysfunction in Parkinson's Disease: Application and Current Directions
Jessica S Calleo (2012)
linesterase inhibitors for dementia with Lewy bodies . Parkinson ' s disease dementia and cognitive impairment in Parkinson ' s disease
M Rolinski (2012)
10.1212/WNL.0b013e3182a823ba
Randomized trial of cognitive speed of processing training in Parkinson disease
J. Edwards (2013)
10.1097/01.pra.0000428558.94329.6d
Psychiatric Care in Parkinson’s Disease
Rosa Quelhas (2013)
10.1002/mds.25377
Nonpharmacological enhancement of cognitive function in Parkinson's disease: A systematic review
J. Hindle (2013)
10.1097/FBP.0b013e3283656db6
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
D. Hubbard (2013)
10.1016/j.jns.2013.07.401
Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's Disease psychosis (Acp-103-020)
J. Cummings (2013)
10.1016/S0140-6736(13)62157-1
Pimavanserin as treatment for Parkinson's disease psychosis
S. Fox (2014)



This paper is referenced by
10.1016/j.parkreldis.2021.04.012
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
S. Isaacson (2021)
10.1155/2021/2603641
Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
K. Dashtipour (2021)
10.1097/ICU.0000000000000701
Visual hallucinations in psychiatric, neurologic, and ophthalmologic disease.
K. A. Coerver (2020)
10.1016/j.jchromb.2020.122015
A rapid, simple and highly sensitive UPLC-MS/MS method for quantitation of pimavanserin in plasma and tissues: Application to pharmacokinetics and brain uptake studies in mice.
E. Ezzeldin (2020)
10.1101/2020.06.12.20128967
Efficacy of cognitive behavioral therapy on non-motor symptoms and quality of life in Parkinson's disease: A systematic review and meta-analysis
F. Luo (2020)
10.1111/PAPT.12321
Psychological interventions for people with Parkinson's disease in the early 2020s: Where do we stand?
Nicolò Zarotti (2020)
10.1124/jpet.120.000037
(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent
S. Hjorth (2020)
10.3233/JPD-202047
Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis
S. Isaacson (2020)
10.1007/978-1-0716-0132-7_17
Behavioral and Psychosocial Treatments of Dementia in the Caribbean: Cuba, Dominican Republic, and Puerto Rico
I. Jimenez-Velazquez (2020)
10.1177/0891988720915525
Exploring Nonmotor Neuropsychiatric Manifestations of Parkinson Disease in a Comprehensive Care Setting
Amitha Dhingra (2020)
10.1016/j.jagp.2020.01.193
Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease.
F. Chekani (2020)
10.1007/978-1-0716-0132-7
Caring for Latinxs with Dementia in a Globalized World: Behavioral and Psychosocial Treatments
Hector Y. Adames (2020)
10.1002/mds.28335
Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta‐Analysis
A. Takamiya (2020)
10.1002/gps.5376
Effect of biological treatments on psychotic symptoms in lewy body disease: A systematic review and meta‐analysis of randomized controlled trials
A. Ford (2020)
10.2147/DHPS.S226486
Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression
F. Chekani (2020)
10.1002/ccr3.2462
Effectiveness of clozapine, oxcarbazepine and rivastigmine combination in a bipolar disorder patient with initial cerebral atrophy
P. Morana (2020)
10.1080/00304948.2019.1697613
A Novel Synthesis of Pimavanserin: A Selective Serotonin 5-HT2A Receptor Inverse Agonist
Kun Hu (2020)
10.1007/s11940-019-0545-6
Advances in Management of Psychosis in Neurodegenerative Diseases
K. Rothenberg (2019)
10.1016/j.amp.2019.09.008
Mécanisme d’action de la pimavansérine : le nouvel antipsychotique pour traiter la psychose parkinsonienne
Dalil Cherif Mghari (2019)
10.1177/2045125319882798
Psychotic disorders in late life: a narrative review
R. Tampi (2019)
10.1080/17512433.2019.1623669
Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin
K. Lyons (2019)
10.1016/j.jpsychires.2019.07.005
Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease.
F. Chekani (2019)
NDT_A_201029 2137..2149
Han Zhang (2019)
10.1007/s11920-019-1058-4
Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases
J. Cummings (2019)
10.2147/NDT.S201029
Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis
H. Zhang (2019)
10.1016/b978-0-444-64012-3.00005-8
Behavioral symptomatology and psychopharmacology of Lewy body dementia.
R. Tampi (2019)
10.1080/14737175.2019.1636648
Treatment of psychiatric disturbances in hypokinetic movement disorders
I. Berardelli (2019)
10.1007/978-3-319-97897-0_24
Treatment of Dementia in Parkinson’s Disease
J. G. Goldman (2019)
10.1016/j.jagp.2018.06.008
FDA Approval of Pimavanserin: Response to Absence of Evidence Versus Evidence of Absence-Pimavanserin and the SAPS-PD.
Sarah Schubmehl (2018)
10.1089/jpm.2018.0390
Top Ten Tips Palliative Care Clinicians Should Know About Parkinson's Disease and Related Disorders.
M. Katz (2018)
10.1136/jnnp-2018-318107
Early use of donepezil against psychosis and cognitive decline in Parkinson’s disease: a randomised controlled trial for 2 years
H. Sawada (2018)
Treatment Advances in Parkinson’s Disease Psychosis—Transforming the Standard of Care for Hallucinations and Delusions
Stuart H. Isaacson (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar